| Item | Name | Cat. No. | Tag/Conjugates |
| Anti-SARS-CoV-2 Spike RBD mAbs [Romlusevimab Biosimilar] (MABL-5186) | MABL-5186 | ELISA, FACS, Functional assay, in vivo binding | G1, Lambda |
| Anti-SOST mAbs [Romosozumab Biosimilar] (MABL-5187) | MABL-5187 | ELISA, FACS, Functional assay, in vivo binding | G2, Kappa |
| Anti-IFNA1 mAbs [Rontalizumab Biosimilar] (MABL-5188) | MABL-5188 | ELISA, FACS, Functional assay, in vivo binding | G2, Kappa |
| Anti-RSPO3 mAbs [Rosmantuzumab Biosimilar] (MABL-5189) | MABL-5189 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-PDCD1/CD279/PD1 mAbs [Rosnilimab Biosimilar] (MABL-5190) | MABL-5190 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-FOLH1/GCPII/PSMA mAbs [Rosopatamab Biosimilar] (MABL-5191) | MABL-5191 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-DLL3 mAbs [Rovalpituzumab Biosimilar] (MABL-5192) | MABL-5192 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-ITGAL/CD11A/LFA1A and ITGB2/CD18 mAbs [Rovelizumab Biosimilar] (MABL-5193) | MABL-5193 | ELISA, FACS, Functional assay, in vivo binding | G4, Kappa |
| Anti-FCGRT/FcRn mAbs [Rozanolixizumab Biosimilar] (MABL-5194) | MABL-5194 | ELISA, FACS, Functional assay, in vivo binding | G4, Kappa |
| Anti-ICOS/CD278 mAbs [Rozibafusp Biosimilar] (MABL-5195) | MABL-5195 | ELISA, FACS, Functional assay, in vivo binding | G2, Kappa |
| Anti-PDCD1/CD279/PD1 mAbs [Rulonilimab Biosimilar] (MABL-5196) | MABL-5196 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-ERBB2/CD340/HER2;CD3E mAbs [Runimotamab Biosimilar] (MABL-5197) | MABL-5197 | ELISA, FACS, Functional assay, in vivo binding | G1;G1, Kappa;Kappa |
| Anti-PDCD1/CD279/PD1;TIGIT/WUCAM/VSTM3 mAbs [Rilvegostomig Biosimilar] (MABL-5171) | MABL-5171 | ELISA, FACS, Functional assay, in vivo binding | G1;G1, Kappa;Lambda |
| Anti-SARS-CoV-2 Spike RBD mAbs [Rimteravimab Biosimilar] (MABL-5172) | MABL-5172 | ELISA, FACS, Functional assay, in vivo binding | G1, na |
| Anti-FOLR1 mAbs [Rinatabart Biosimilar] (MABL-5173) | MABL-5173 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-PDGFRB/CD140B mAbs [Rinucumab Biosimilar] (MABL-5174) | MABL-5174 | ELISA, FACS, Functional assay, in vivo binding | G4, Kappa |
| Anti-MS4A1/CD20 mAbs [Ripertamab Biosimilar] (MABL-5175) | MABL-5175 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-IL23A mAbs [Risankizumab Biosimilar] (MABL-5176) | MABL-5176 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-MS4A1/CD20 mAbs [Rituximab Biosimilar] (MABL-5177) | MABL-5177 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-PcrV type III secretion system mAbs [Rivabazumab Biosimilar] (MABL-5178) | MABL-5178 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
联系我们
Copyright © 2012-2029 西安迈博睿(Mabioway)生物科技有限公司 版权所有
地址:陕西省西安市浐灞生态区广运潭大道南段4555号长安大学科技园4号楼A单元2层
电话:15339069646 邮箱:info@mabioway.cn
